⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Montara Therapeutics Announces Development Candidate for First BrainOnly™-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer
globenewswire.com
XNCR
AMGN
Xencor to Participate at Upcoming Investor Conferences
businesswire.com
XNCR
Xencor Reports Third Quarter 2025 Financial Results
businesswire.com
XNCR
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
businesswire.com
XNCR
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
businesswire.com
XNCR